Pivotal-Point Tracking Guardant Health (GH): 39% Revenue Growth in Q3 and Increased Annual Guidance in [Oncology!]
Reading Time: 1 minute
Guardant Health's stock saw a significant rally on October 30, 2025, after the company announced its financial results for the third quarter the day before. Guardant Health, a leading precision oncology company specializing in liquid biopsies for cancer diagnosis and monitoring, reported a revenue growth of 39% to $265.2 million, significantly surpassing consensus estimates. This growth was broadly supported by its oncology, screening, as well as biopharma and data segments, with the oncology test volume alone increasing by 40%. The excellent quarterly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
